

Reference:	FOI.21224.26
Subject:	Atopic Dermatitis
Date of Request:	3 August 2026

Requested:

1. How many patients were treated in the last 4 months (April to July 2026) by the dermatology department with each of the following products:

- Abrocitinib
- Acitretin
- Alitretinoin
- Azathioprine
- Baricitinib
- Ciclosporin
- Dupilumab
- Lebrikizumab
- Methotrexate
- Mycophenolate mofetil
- Pimecrolimus
- Phototherapy (UVB or PUVA) - for Atopic Dermatitis only
- Tacrolimus ointment
- Tralokinumab
- Upadacitinib
- Nemolizumab

2. In the last 4 months, how many new patients have been initiated* on the following treatments by the dermatology department

- Abrocitinib
- Baricitinib
- Dupilumab
- Lebrikizumab
- Tralokinumab
- Upadacitinib
- Nemolizumab

*Patients are considered initiated if they have not been treated in the previous 8 months with any of the drugs that are part of the named regimen

3. Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group:

- 6 months to 5
- Age 6-11
- Age 12-17
- Age 18 and above

4. How many patients have received treatment by the dermatology department for Prurigo Nodularis in the last 4 months with each of the following products:

- Dupilumab
- Nemolizumab

Response:

Where the figures in the tables have been replaced with an asterisk (*), Hywel Dda University Health Board (UHB) is unable to provide you with the exact number of patients due to the low number of patients (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000 (FoIA). This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations (UK GDPR) as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

1. The UHB provides within the table below, the number of patients that were issued with the named biologic medications by the Dermatology department, during the period 1 April to 31 July 2026.

Medication	Number
Abrocitinib	*
Acitretin	56
Alitretinoin	*
Azathioprine	15
Baricitinib	0
Ciclosporin	17
Dupilumab	162
Lebrikizumab	*
Methotrexate	126
Mycophenolate mofetil	17
Pimecrolimus	*
Phototherapy (UVB or PUVA) - for Atopic Dermatitis only	*
Tacrolimus ointment	0
Tralokinumab	8
Upadacitinib	8
Nemolizumab	*

2. The UHB provides within the table overleaf, the number of patients initiated on the named biologic medications by the Dermatology department, during the period 1 April to 31 July 2026.

Medication	Number
Abrocitinib	*
Baricitinib	0
Dupilumab	7
Lebrikizumab	0
Tralokinumab	0
Upadacitinib	0
Nemolizumab	*

3. The UHB provides within the table below, the number of patients in each of the listed age groups that were issued with the biologic medications listed in question 1, during the period 1 April to 31 July 2026.

Age Group	Number
6 months to 5	9
Age 6 - 11	16
Age 12 - 17	32
Age 18 and above	474

4. The UHB provides within the table below, the number of patients treated by the Dermatology department for Prurigo Nodularis, with the listed medications, during the period 1 April to 31 July 2026.

Medication	Number
Dupilumab	5
Nemolizumab	0